BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Thrombotargets Corporation 

2530 Meridian Parkway
Suite 3024
Durham  North Carolina  27713  U.S.A.
Phone: 919-806-4254 / 919-806-4322 Fax: 919-806-4870


SEARCH JOBS
Thrombotargets is an innovative drug discovery and development group of biotech companies developing new medicines based on advances in recombinant DNA and small molecule drug technologies. Thrombotargets´s programs leverage the company’s haemostasis expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic disorders.

Thrombotargets group is comprised by three companies; Thrombotargets Corporation (Durham, NC, USA.) is responsible for Drug Development and Business Managment; Thrombotargets Europe (Barcelona, Spain) for Target Identification, Lead Validation, Lead Optimization and High Througput Screening and Biotech Libraries (Girona, Spain) for engineered targeted libraries.

Thrombotargets´s strategy is to build stockholder value by discovering new leads and advancing them to clinical phases.

With a primary focus on therapeutics for Haemostasis and Thrombotic diseases, Thrombotargets´s objective is to identify, optimize and develop highly efficacious biotech and small molecule leads with low risk profiles and large market opportunities.

Thrombotargets will achieve their objectives by operating a balanced risk business strategy:

1. Invest in our own discovery and development programs and drive these through to clinical phases before partnering the candidate with pharmaceutical companies. Thrombotargets will be compensated for this innovation and effort primarily through license fees, milestones and royalties on drug sales.
2. Collaborate with the pharmaceutical industry leaders to share the investment and the rewards associated with generating market outcomes for innovative new therapies.
3. Through the in-licensing of programs at stages of development that complement and balance our existing internal portfolio, Thombotargets leverage external innovation

Proprietary Technology
Thrombotargets has developed and adapted to High Throughput Screening (HTS), a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary HTS Platforms named BioPlatformScreenTM, the Thrombotargets group is creating a continuously novel and promising pipeline. Presently, two of Thrombotargets most innovative drug candidates, TH-103MH, a novel antihemorrhagic human recombinant protein to be use topically, and TT-105, a novel anticoagulant monoclonal antibody, are undergoing Preclinical trials; these programs will begin Phase I clinical trials Q4, 2007. Recently we begun a new antifibrinolytic program (TT-111 and TT-112) in collaboration with ASINEX, Rusia due to results in the explotation of our BioplatformScreen Technology.

Current Alliances
  • Asinex, Moscow, Russia
  • Specs, Delft, Netherland
  • Villapharma, Murcia, Spain
  • Lippso, Girona, Spain
  • IUCT, Barcelona, Spain

    Intellectual Property Status
    Thrombotargets patents state protect our intellectual property and permit the commercialization of our technologies and compounds.

    Board of Directors
  • Javier Pedreno, Chief Executive Officer and President
  • Luis Caveda, Chief Operating Officer
  • Luis Aced , Chief Financial Officer
  • Lina Badimon, Associated Scientific Consultant
  • Juan Ramon Rodriguez, R&D Director
  • Rosa Fernandez , Project Development Director
  • Ignasi Miquel, Strategic Aliances Director

    Scientific Advisory Board
  • Lina Badimon, Cardiovascular Research Center, Barcelona, Spain
  • Cam Patterson, Carolina Cardiovascular Biology Center, North Carolina, US
  • Ira Lamster, School of Dental and oral Surgery, University of Columbia, New York, US
  • Juanjo Badimón, Cardiovascular Institute and Center for Cardiovascular Health, Mount Sinai School of Medicine
  • Javier Pedreño, Thrombotargets, Spain

    Last Updated: 07-20-2007

     Key Statistics


    Email: partnering@thrombotargets.com
    Ownership: Private

    Web Site: Thrombotargets Corporation
    Employees: 10
    Symbol: 
     



  • Industry
    Biotechnology






     Company News
    Thrombotargets Corporation and Dr. Cam Patterson to Create a Joint Venture 7/25/2007 12:52:50 PM    More...
    Thrombotargets Corporation and Magellan Bioscience Group, Inc. to Collaborate 7/25/2007 12:44:23 PM    More...
    Steven Hite Appointed Chief Operating Officer of Thrombotargets Corporation 7/25/2007 12:38:52 PM    More...
    Thrombotargets Corporation Announces the Membership of its Scientific Advisory Board 7/25/2007 12:33:28 PM    More...
    Thrombotargets Corporation Relocates to Research Triangle Park in North Carolina 4/23/2007 2:54:35 PM    More...
    Thrombotargets Corporation Europe Inagurates New Facilities at the National Biotechnology Center in Madrid, Spain 4/23/2007 2:52:45 PM    More...

    //-->